COGNITION THERAPEUTICS INC

Cognition is a clinical-stage biopharmaceutical company that discovers and develops small molecule drug candidates for age-related degenerative disorders of the central nervous system and retina. The company focuses on developing disease-modifying therapies designed to protect neuronal synapses from toxic protein oligomers. Its primary pipeline candidate is zervimesine, also identified as CT1812, an orally administered therapeutic being evaluated for Alzheimer’s disease and dementia with Lewy bodies. Its target recipients are patients experiencing cognitive decline, mild cognitive impairment, and associated neurodegenerative conditions.

In terms of clinical scale, more than 780 participants have received zervimesine across various clinical trials. The company conducts its ongoing Phase 2 START study across 45 clinical trial sites in collaboration with a specialized research consortium. Its regulatory engagements span agencies in the United States and Europe, including interactions with the United States Food and Drug Administration and guidance from the European Medicines Agency. The provided text does not state the location of the company's headquarters.

Summary of the business section of Cognition Therapeutics's latest annual report, written by StockData.

“As of March 1, 2026, we had 14 employees, 14 of whom were full-time and 8 of whom were engaged in research and development activities.”